Role of gene enhancer elements in colon cancer
基因增强子元件在结肠癌中的作用
基本信息
- 批准号:8633432
- 负责人:
- 金额:$ 39.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdultAmericanBackBindingBiological AssayBiological ProcessCancer EtiologyCancer PatientCell LineCellsCessation of lifeChIP-seqChromosomesClinicalColonColon CarcinomaColonic NeoplasmsColorectal NeoplasmsDNADNA SequenceDataDerivation procedureDiseaseDisease ProgressionDistalEmbryoEnhancersEpigenetic ProcessEpitheliumEventFibroblastsFrequenciesFunctional RNAGene ExpressionGene MutationGenesGeneticGenetic Enhancer ElementGenomeGenomicsGoalsHistone H3HumanHybridsIndiumKnock-in MouseLearningLocationLuciferasesLysineMalignant NeoplasmsMapsMediatingMemoryMethodsModelingMolecular ConformationMono-SMutationNeoplasm MetastasisPhenotypeProcessRelative (related person)ReporterRoleSamplingSignal TransductionSomatic CellSomatic MutationStagingTechnologyTestingTherapeutic StudiesTumor-DerivedVariantcancer cellcarcinogenesiscohortcolon cancer cell linegenome-wideinduced pluripotent stem cellinnovationinsightintestinal epitheliummortalitynovelresearch studyrestorationtranscription factortumortumor progressionvector
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this proposal is to identify genetic and epigenetic alterations occurring at gene enhancer elements in colon cancer, and to gain insights into how these events mediate disease progression. Cancer is due to the progressive accumulation of mutations in DNA, as well as heritable changes in gene expression caused by mechanisms other than mutations in the underlying DNA sequence, so called epigenetic alterations. Gene enhancer elements are short regions of DNA to which transcription factors bind in order to increase the expression of a gene. Enhancers are almost certainly altered at both the genetic and epigenetic level in cancer, although the extent by which this occurs is unknown. Using state of the art ChIP-seq technology, we identified the locations of gene enhancer elements across the entire genome in cells derived from human colon cancer and normal colon. While the locations of many enhancers remain unchanged, thousands of enhancer loci differ between normal colon and colon cancer cells. We call these regions variations at enhancer loci, or VELs. We hypothesize that VELs, which either contain somatic mutations or are purely epigenetically derived, contribute to the formation and progression of colon tumors. Three specific aims are proposed. In Aim 1 we will systematically assess the relationship between VELs and colon cancer progression through characterization of VELs in a cohort of well-characterized primary cell lines that comprehensively capture all of the clinical stages of colon cancer. In Aim 2, we will conduct DNA sequencing of VELs in tumor and matched normal DNA from ten colon cancer patients to identify somatic mutations that may have accrued at gene enhancer elements during carcinogenesis. In Aim 3, we will assess the plasticity and reversibility of the VELs through innovative experiments in which colon cancer cells are reverted to the embryonic state and then re- differentiated into colon epithelium. The successful completion of these Aims will accelerate our understanding of epigenetics and the role of a class of non-coding functional elements in colon cancer, which could ultimately have important implications for therapeutic studies aimed at targeting restoration of aberrantly expressed genes in colon cancer.
描述(由申请人提供):该提案的总体目标是识别结肠癌基因增强子元件处发生的遗传和表观遗传改变,并深入了解这些事件如何介导疾病进展。癌症是由于 DNA 突变的逐渐积累以及由基础 DNA 序列突变以外的机制引起的基因表达的遗传性变化(所谓的表观遗传改变)造成的。基因增强子元件是 DNA 的短区域,转录因子与其结合以增加基因的表达。几乎可以肯定,增强子在癌症的遗传和表观遗传水平上都发生了改变,尽管这种改变发生的程度尚不清楚。利用最先进的 ChIP-seq 技术,我们确定了源自人类结肠癌和正常结肠的细胞中基因增强子元件在整个基因组中的位置。虽然许多增强子的位置保持不变,但正常结肠和结肠癌细胞之间有数千个增强子位点不同。我们将这些区域称为增强子基因座变异(VEL)。我们假设含有体细胞突变或纯粹表观遗传衍生的 VEL 有助于结肠肿瘤的形成和进展。提出了三个具体目标。在目标 1 中,我们将通过在一组全面捕获结肠癌所有临床阶段的充分表征的原代细胞系中对 VEL 进行表征,系统地评估 VEL 与结肠癌进展之间的关系。在目标 2 中,我们将对肿瘤中的 VEL 和来自 10 名结肠癌患者的匹配正常 DNA 进行 DNA 测序,以识别在癌发生过程中基因增强子元件可能产生的体细胞突变。在目标 3 中,我们将通过创新实验评估 VEL 的可塑性和可逆性,其中结肠癌细胞恢复到胚胎状态,然后重新分化为结肠上皮。这些目标的成功完成将加速我们对表观遗传学和一类非编码功能元件在结肠癌中的作用的理解,这最终可能对旨在恢复结肠癌中异常表达基因的治疗研究产生重要影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANFORD D. MARKOWITZ其他文献
SANFORD D. MARKOWITZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANFORD D. MARKOWITZ', 18)}}的其他基金
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration
15-前列腺素脱氢酶在组织修复和再生中的化学、结构和细胞信号传导研究
- 批准号:
10627860 - 财政年份:2021
- 资助金额:
$ 39.48万 - 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
- 批准号:
9406781 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
- 批准号:
10524057 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
- 批准号:
10305660 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
- 批准号:
9183207 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
针对癌症风险、预防和治疗中的 15-前列腺素脱氢酶 (15-PGDH)
- 批准号:
10058813 - 财政年份:2016
- 资助金额:
$ 39.48万 - 项目类别:
Role of gene enhancer elements in colon cancer
基因增强子元件在结肠癌中的作用
- 批准号:
8449075 - 财政年份:2012
- 资助金额:
$ 39.48万 - 项目类别:
Role of gene enhancer elements in colon cancer
基因增强子元件在结肠癌中的作用
- 批准号:
8289140 - 财政年份:2012
- 资助金额:
$ 39.48万 - 项目类别:
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention
以 15-PGDH 为靶点进行结肠癌的预后、预测、治疗和预防
- 批准号:
8555227 - 财政年份:2011
- 资助金额:
$ 39.48万 - 项目类别:
相似国自然基金
单核细胞产生S100A8/A9放大中性粒细胞炎症反应调控成人Still病发病及病情演变的机制研究
- 批准号:82373465
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SERPINF1/SRSF6/B7-H3信号通路在成人B-ALL免疫逃逸中的作用及机制研究
- 批准号:82300208
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于动态信息的深度学习辅助设计成人脊柱畸形手术方案的研究
- 批准号:82372499
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Preventing Firearm Suicide Deaths Among Black/African American Adults
防止黑人/非裔美国成年人因枪支自杀死亡
- 批准号:
10811498 - 财政年份:2023
- 资助金额:
$ 39.48万 - 项目类别:
Informing alcohol policy: The impact of evidence-based alcohol warnings on consumption
告知酒精政策:基于证据的酒精警告对消费的影响
- 批准号:
10565120 - 财政年份:2023
- 资助金额:
$ 39.48万 - 项目类别:
Individualized medicine to predict and prevent chemotherapy-related heart failure
预测和预防化疗相关心力衰竭的个体化药物
- 批准号:
10714111 - 财政年份:2023
- 资助金额:
$ 39.48万 - 项目类别:
Trauma and Cardiometabolic Health in an American Indian Community
美洲印第安人社区的创伤和心脏代谢健康
- 批准号:
10657249 - 财政年份:2023
- 资助金额:
$ 39.48万 - 项目类别:
Identifying the Causes of the Stagnation in National U.S. Cardiovascular Disease Mortality
查明美国全国心血管疾病死亡率停滞不前的原因
- 批准号:
10585800 - 财政年份:2023
- 资助金额:
$ 39.48万 - 项目类别: